GlassScriptPhysician profile
Jeffrey Seley
NPI 1881700532
$1,846.80
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $165 · 2021: $399 · 2022: $542.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $325.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $308.53 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $187.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.92 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $95.49 | 2019-2022 | |
| Shire North American Group INC | $95.16 | 2019 | |
| Acadia Pharmaceuticals INC | $92.06 | 2019-2022 | |
| Lundbeck LLC | $90.68 | 2019-2021 | |
| Allergan, INC. | $88.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $65.97 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $64.40 | 2022 | |
| Ironshore Pharmaceuticals INC. | $63.06 | 2019-2022 | |
| Abbvie INC. | $61.75 | 2021-2022 | |
| Almatica Pharma LLC | $50.37 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.54 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $17.81 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Seley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.